|
|
| Sposito,A.C.; Mansur,A.P.; Maranhão,R.C.; Rodrigues-Sobrinho,C.R.M.; Coelho,O.R.; Ramires,J.A.F.. |
| Etofibrate is a hybrid drug which combines niacin with clofibrate. After contact with plasma hydrolases, both constituents are gradually released in a controlled-release manner. In this study, we compared the effects of etofibrate and controlled-release niacin on lipid profile and plasma lipoprotein (a) (Lp(a)) levels of patients with triglyceride levels of 200 to 400 mg/dl, total cholesterol above 240 mg/dl and Lp(a) above 40 mg/dl. These patients were randomly assigned to a double-blind 16-week treatment period with etofibrate (500 mg twice daily, N = 14) or niacin (500 mg twice daily, N = 11). In both treatment groups total cholesterol, VLDL cholesterol and triglycerides were equally reduced and high-density lipoprotein cholesterol was increased.... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Etofibrate; Niacin; Lipoprotein (a); Triglycerides; Cholesterol. |
| Ano: 2001 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2001000200004 |
| |
